CTNM Stock Analysis: Buy, Sell, or Hold?
CTNM - Contineum Therapeutics, Inc. Class A Common Stock
$12.46
-0.88 (-6.60%)
▼
5d:
+0.32%
30d:
-18.77%
90d:
+0.4%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
CTNM is down 11.5% this week, but smart money is accumulating calls. Top strike: $17.5 2026-04-17 with 6 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When CTNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTNM is currently trading at $12.46, which is considered oversold relative to its 30-day fair value range of $12.70 to $15.26.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $11.80, while resistance sits at $14.20. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (78th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $22.00 (+76.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $11.80, while resistance sits at $14.20. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (78th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $22.00 (+76.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$12.70 -
$15.26
Company Quality Score
55/100
(HOLD)
Options IV Signal
78th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
61.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 78th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 76.6% below Wall St target ($22.00)
Fair Price Analysis
30-Day Fair Range
$12.70 -
$15.26
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.56
(28.5%)
Support & Resistance Levels
Support Level
$11.80
Resistance Level
$14.20
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.73
Wall Street Target
$22.00
(+76.6%)
Share & Embed Analysis
Last updated: March 30, 2026 6:36 PM ET
Data refreshes hourly during market hours. Next update: 7:36 PM
Data refreshes hourly during market hours. Next update: 7:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTNM showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 44 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
